Another strength of our analysis stems from the ability to risk-stratify T1 CRC and estimate mortality rates for individual tumor biomarker profiles based on published research.7 Although multiple studies5,6,7,8,9,17 have reported that APC, TP53, KRAS, and BRAFV600E were key drivers of CRC, the study by Schell et al7 was the first to demonstrate multigene interaction between these genetic factors and their effect on overall survival. The gene discussed is KRAS; the disease is colorectal carcinoma.